| Title | Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced intensity conditioning HCT. Blood Advances |
| Publication Type | Journal Article |
| Year of Publication | 2023 |
| Authors | Geerlinks, A, Scull, B, Krupski, C, Fleischmann, R, Pulsipher, MA, Eapen, M, Connelly, JA, Bollard, CM, Pai, SY, Duncan, C, Kean, LS, Baker, KS, Burroughs, L, ,, Shenoy, S, Roehrs, P, Hanna, R, Talano, JA, Schultz, KR, Stenger, EO, Lin, H, Zoref-Lorenz, A, McClain, KL, Jordan, MB, Man, TK, Allen, CE, Marsh, RA |
| Journal | Blood Advances |
| Date Published | 04/2023 |
| DOI | 10.1182/bloodadvances.2022009478 |
